Fig. 1

Chidamide and venetoclax demonstrate synergistic anti-myeloma efficacy in HMCLs in vitro. A HMCLs were treated with the indicated concentrations of chidamide and venetoclax for 24 h and 48 h, then CCK-8 assay was performed to test cell viability. B HMCLs were treated with the indicated concentrations of venetoclax ± 0.5 or 2 μM chidamide for 48 h, and the CCK-8 kit was used to test the cell viability. C From the dose–response curves, the CI of the two drugs were calculated using CompuSyn software, with CI < 1 indicating a synergistic interaction. D Cell growth was monitored every 24 h for a consecutive 4 days. The values indicate mean ± SD for at least three independent experiments performed in triplicate